Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
Retrieved on:
Monday, March 20, 2023
DSM-IV codes, Society, University of Pittsburgh, University, Pediatrics, Therapy, Phenylketonuria, SIMD, Aes, Adverse, AbbVie, Publication, Biomarker, Doctor of Philosophy, CBS, PKU, Research and development, Homocysteine, Plasma, Homocystinuria, Genetics, HCU, MD, Patient, Nature, Met, Annual general meeting, HCY, Extrapyramidal system, UPMC, Cystathionine, Synthetic biology, Medical genetics, Pharmaceutical industry, Dietary supplement, Research
In separate poster presentations, the company also presented clinical data and preclinical data related to its homocystinuria (HCU) program.
Key Points:
- In separate poster presentations, the company also presented clinical data and preclinical data related to its homocystinuria (HCU) program.
- “We were delighted to review these encouraging findings from our two rare metabolic disease programs among the expert metabolic clinicians who attend the SIMD meeting,” said Dave Hava, Chief Scientific Officer and Head of Research and Development at Synlogic.
- Clinical data presented included positive data from the Phase 1 study evaluating SYNB1353 in healthy volunteers using a dietary model of HCU.
- Posters presented at the SIMD meeting are posted on the Publications page of the Synlogic website.